Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? The Globe and Mail
Covered in this story
What has happened since
- Pfizer is up 10.2% since this was published, 15 days ago.
- Novo Nordisk is up 5.8% since this was published, 15 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 50 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.